In the univariate survival analysis, advanced stage, FIGO III-IV (P = 0.002), presence of residual tumour in operation (P = 0.008), presence of ascites (P = 0.036), non-sensitivity to platinum-based chemotherapy (P = 0.001), incomplete response to treatment (P = 0.006), and high Ki-67 expression (P = 0.037) were significant predictors of shorter RFS. Here, MKI67 is linked to neoplasm.